Protective Effects of Li-Fei-Xiao-Yan Prescription on Lipopolysaccharide-Induced Acute Lung Injury via Inhibition of Oxidative Stress and the TLR4/NF-κB Pathway

Li-Fei-Xiao-Yan prescription (LFXY) has been clinically used in China to treat inflammatory and infectious diseases including inflammatory lung diseases. The present study was aimed at evaluating the potential therapeutic effects and potential mechanisms of LFXY in a murine model of lipopolysacchari...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Lie-Qiang, Yu, Xiu-Ting, Gui, Shu-Hua, Xie, Jian-hui, Wang, Xiu-Fen, Su, Zu-Qing, Li, Yu-Cui, Lai, Xiao-Ping, Zhan, Janis Ya-Xian, Xie, You-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382312/
https://www.ncbi.nlm.nih.gov/pubmed/28424738
http://dx.doi.org/10.1155/2017/1791789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382312/
https://www.ncbi.nlm.nih.gov/pubmed/28424738
http://dx.doi.org/10.1155/2017/1791789

Ejemplares similares